Regenics AS is a private Norwegian biotechnology company based in Oslo. The company develops a range of wound care products, with a current pipeline of two medical devices and one novel drug.
Target diagnoses and applications include burns, diabetic wounds, chronic wounds, and enzymatic wound debridement. One of our major innovations, HTX™, is a bioactive substance sourced and purified from unfertilized salmon roe.
We are committed to greatly improving treatment outcomes in advanced wound management. Combining the unique healing properties of salmon roe with other marine ingredients, our products aim to redefine current standards of care.